Anti-PPAR gamma (phospho S112) antibody (ab60953)


  • Product nameAnti-PPAR gamma (phospho S112) antibody
    See all PPAR gamma primary antibodies
  • Description
    Rabbit polyclonal to PPAR gamma (phospho S112)
  • Specificityab60953 detects endogenous levels of PPAR gamma only when phosphorylated at serine 112. This antibody reacts with both forms (isoform 1 and 2) of human PPAR-gamma.
  • Tested applicationsICC/IF, IHC-P, ELISA, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic phosphopeptide derived from human PPAR gamma around the phosphorylation site of serine 112 (P-A-SP-P-P).

  • Positive control
    • Jurkat cell extracts treated with Paclitaxel.



Our Abpromise guarantee covers the use of ab60953 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 1 - 5 µg/ml.
IHC-P Use a concentration of 4 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ELISA 1/10000.
WB 1/500 - 1/1000. Detects a band of approximately 58 kDa (predicted molecular weight: 58 kDa).


  • FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
  • Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
  • Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
    Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
    Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
    Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
  • Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CIMT1 antibody
    • GLM1 antibody
    • HUMPPARG antibody
    • NR1C3 antibody
    • Nuclear receptor subfamily 1 group C member 3 antibody
    • OTTHUMP00000185032 antibody
    • OTTHUMP00000185036 antibody
    • PAX8/PPARG Fusion Gene antibody
    • Peroxisome proliferator activated nuclear receptor gamma variant 1 antibody
    • Peroxisome proliferator activated receptor gamma 1 antibody
    • Peroxisome Proliferator Activated Receptor gamma antibody
    • Peroxisome proliferator-activated receptor gamma antibody
    • PPAR gamma antibody
    • PPAR-gamma antibody
    • PPARG antibody
    • PPARG_HUMAN antibody
    • PPARG1 antibody
    • PPARG2 antibody
    • PPARG3 antibody
    • PPARgamma antibody
    see all

Anti-PPAR gamma (phospho S112) antibody images

  • All lanes : Anti-PPAR gamma (phospho S112) antibody (ab60953) at 1/500 dilution

    Lane 1 : Jurkat cell extracts treated with Paclitaxel (1uM, 24hours)
    Lane 2 : Jurkat cell extracts treated with Paclitaxel (1uM, 24hours) with immunising peptide

    Predicted band size : 58 kDa
    Observed band size : 58 kDa
  • ICC/IF image of ab60953 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab60953, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • ab60953 (4µg/ml) staining PPAR gamma in human ureter tissue using an automated system (DAKO Autostainer Plus). Using this protocol there is strong nuclear staining of blood lymphocytes.
    Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer citrate pH6.1 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.

References for Anti-PPAR gamma (phospho S112) antibody (ab60953)

This product has been referenced in:
  • Kolli V  et al. Partial Agonist, Telmisartan, Maintains PPAR? Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass. PLoS One 9:e96323 (2014). WB . Read more (PubMed: 24810249) »
  • Liu J  et al. Sex-specific perinatal nicotine-induced asthma in rat offspring. Am J Respir Cell Mol Biol 48:53-62 (2013). Read more (PubMed: 23002101) »

See all 4 Publications for this product

Product Wall

Application Western blot
Sample Mouse Cell lysate - whole cell (3T3-L1 adipocytes)
Loading amount 50 µg
Specification 3T3-L1 adipocytes
Treatment 5uM troglitazone, 50nM FGF21 or both
Gel Running Conditions Reduced Denaturing (12% gel)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 21°C

Abcam user community

Verified customer

Submitted Nov 01 2010

Application Western blot
Sample Sheep Cell lysate - whole cell (PAECs)
Loading amount 25 µg
Specification PAECs
Gel Running Conditions Reduced Denaturing (10 %)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 23°C

Ms. Nancy Tseng

Verified customer

Submitted Sep 14 2012

Thank you for your enquiry.

This antibody reacts with both forms (isoform 1 and 2) of human PPAR-gamma with accession numbers P37231-1 and P37231-2 (

If you have any other questions, please d...

Read More

Thank you for your reply.

For the phospho-specific antibody, ab60953,you should avoid milk. The protocol is below:

Cell Lysis and WB Protocol

Cell Lysis Protocol

1. For adherent cells, wash cells with Wash Buffer...

Read More

I am very pleased to hear you would like to accept our offer and test ab60953 andab70405 in sheep. These codes will give you: 1 free primary antibody each before the expiration date. To redeem this offer, please submit an Abreview for sheep and include...

Read More

Thank you for contacting us and reporting the problems observed in using anti-PPAR gamma antibody (ab60953) to detect phosphorylated S112.

I am currently looking into whether the HeLa cells used for staining, as presented on the datasheet fo...

Read More
Abcam has not validated the combination of species/application used in this Abreview.
Application Western blot
Sample Rat Cell lysate - whole cell (pulmonary artery smooth muscle cell)
Loading amount 20 µg
Specification pulmonary artery smooth muscle cell
Treatment (0.01,0.1,1,12.5,25,50 µM)of Sodium Tanshinon ?Asilate for 60hrs
Gel Running Conditions Non-reduced Denaturing (10% gel)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 37°C

Mr. Kai Yang

Verified customer

Submitted Oct 04 2011